What good are whizzy new drugs if the world can’t afford them?
Bringing gene therapies and obesity drugs to the masses will require financial innovation too, says Steven Pearson
IN RECENT YEARS biotechnology and pharmaceutical science have produced quantum leaps that both offer great opportunity and pose great risk. Gene therapies for rare conditions and obesity drugs for larger segments of society could transform health for the better. But for that to happen, policymakers and the companies behind these new treatments need to adapt quickly to the daunting cost challenges associated with them.
More from By Invitation
Clearing Ukraine’s mines is crucial for global food security, say Howard Buffett and Tony Blair
With the right sort of technology and financing, it needn’t take a century
Mario Draghi outlines his plan to make Europe more competitive
The continent needs investment on a par with the Marshall Plan and a lot more innovation, says the former central banker
Large language models will upend human rituals
The results could be disturbing, argue Marion Fourcade and Henry Farrell
Kamala Harris has good vibes. Time for some good policies
Steven Teles, a political scientist, on the three Ps that the Democratic nominee should focus on
Break the taboos propping up unsustainable debt, pleads a former central banker
Murtaza Syed on overcoming fear of restructuring, cajoling creditors and encouraging the IMF to be candid
Mark Zuckerberg and Daniel Ek on why Europe should embrace open-source AI
It risks falling behind because of incoherent and complex regulation, say the two tech CEOs